RUBY - Rubius Therapeutics drops 5% despite Q4 beat

Rubius Therapeutics ([[RUBY]] -5.1%) reports Q4 net loss was $40.5M or $0.50 per share, compared to $44.5M or $0.56 last year same quarter.Company invested $25.6M in R&D related to its novel RED PLATFORM and towards expanding and advancing its product pipeline.G&A expenses were $14.1M vs. $14.9M last year.As of December 31, 2020, cash, cash equivalents and investments were $176.3M as compared to $283.3M as of December 31, 2019.GAAP EPS of -$0.50 beats consensus by $0.03.Reported initial key takeaways in January 2021 showing RTX-240 stimulates innate and adaptive immunity; additional clinical results to be presented in early 2021.“Last year was one of strong execution for Rubius Therapeutics as we advanced our clinical trials in oncology and strengthened our in-house manufacturing capabilities. 2021 is set to be an important year in which we plan to further advance our programs and report the clinical results from the Phase 1 trial of RTX-240 in advanced solid

For further details see:

Rubius Therapeutics drops 5% despite Q4 beat